[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100175494":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":21,"centralContacts":25,"locations":32,"responsibleParty":53,"collaborators":30,"id":55,"slug":30,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":30,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":30,"maxAge":62,"enrollmentInfo":63,"targetDuration":30,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":74,"overallStatus":35,"whyStopped":30,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Weill Medical College of Cornell University","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Use of high dose chemotherapy","Use of chemotherapy without removal of the disease ovary.",[12],"Procedure: surgery to remove ovaries or high dose chemotherapy",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","surgery to remove ovaries or high dose chemotherapy","oophorectomy to remove a disease ovary.",[9],[20],"Use of high dose chemotherapy without removal of disease ovary.",[22],{"name":23,"affiliation":5,"role":24},"Glenn Schattman, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Rodriq E. Stubbs, NP","CONTACT","646-962-3276",null,"res2011@med.cornell.edu",[33],{"facility":34,"status":35,"city":36,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine","RECRUITING","New York","10021","United States",{"type":40,"coordinates":41},"Point",[42,43],-74.00597,40.71427,{"lat":43,"lon":42},[46,48,52],{"name":47,"role":28,"phone":29,"phoneExt":30,"email":31},"Rodriq Stubbs, NP",{"name":49,"role":28,"phone":50,"phoneExt":30,"email":51},"Mitasha C. Joseph, RN, MPA","646-962-3382","mij2008@med.cornell.edu",{"name":23,"role":24,"phone":30,"phoneExt":30,"email":30},{"type":54,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100175494",false,"NCT01558544","Cryopreservation of Ovarian Tissue","Cryopreservation of Ovarian Tissue for Potential In Vitro Maturation or Autologous Transplantation","Inclusion Criteria:\n\n* Females 0-45 years of age who are premenopausal\n* Treatment plan that will likely result in premature menopause or premature ovarian failure\n* This includes patients receiving:\n* Cancer treatment with abdominal pelvic irradiation and\u002For high dose chemotherapy\n* Surgery that requires removal of ovaries for medical condition or disease, e.g. Prophylactic oophorectomy in BRCA patients\n* Patient is unable or unwilling to pursue fertility preservation by freezing oocytes or embryos.\n* Previous treatment for cancer is acceptable if patient still has ovarian function\n* Patient is medically stable enough to undergo surgery (cleared for anesthesia)\n\nExclusion Criteria:\n\n* Patients not meeting the above criteria\n* Patients who have not received medical clearance from their physicians to undergo surgery\n* Patients already experiencing menopause.","FEMALE","45 Years",{"count":64,"type":65},300,"ESTIMATED","INTERVENTIONAL",[68],"NA","The study hopes to contribute to the development of technologies of ovarian tissue freezing-thawing and in vitro maturation of immature eggs such that a person at risk for premature ovarian failure might be able to conceive a genetically related child.",[71,72,73],"Cancer","Risk of Premature Ovarian Failure","Fertility Preservation",[75,76,77,78],"Ovarian tissue cryopreservation","Ovarian tissue transplantation","Fertility preservation","Risk of premature ovarian failure","2025-12-09",{"date":81,"type":82},"2025-12-10","ACTUAL",{"date":84,"type":82},"1997-04",{"date":86,"type":65},"2029-10-31",{"name":5,"class":6},1]